Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.
EBioMedicine · 2024-Dec · PMID 39631145
Progression-free survival
Fig. 2 Outcomes based on baseline FDG-PET staging, period, and rituximab. Progression-free survival by ITT analysis of IFRT+(R)CVP vs. IFRT arms in the A) late-era and B) early era. C) Progression-free survival in all patients in the TROG99.03 trial based on whether baseline FDG-PET was used as a staging modality and D) FDG-PET staged patients by IIT analysis of IFRT+(R)CVP vs. IFRT arms. E) Progression-free survival, per treatment received, of R–CVP treated patients compared with all non-rituximab containing treatments. F) Progression-free survival, per treatment received, of R–CVP treated patients compared with CVP treated patients.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T18:34:16+00:00 |